# BliNK Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blink-biomedical

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.blinkbiomedical.com
- Total disclosed funding: $17M
- Latest round: Series A (Feb 26, 2015)
- Investors on record: 3

## About

BliNK Biomedical SAS specializes in advanced B cell technology for selecting and isolating specific antibody-producing cells, aimed at addressing challenging antigens in therapeutic development.Founded in 2015, BliNK Biomedical SAS operates from Lyon, France, focusing on antibody discovery solutions. The company has undergone no major pivots and is not known to have subsidiaries. The founder's history is not available. BliNK Biomedical has secured a total funding of EUR 1.65 mn in its SERIES A round led by Idinvest Partners in July 2016, which is part of a larger deal amounting to EUR 5.65 mn.BliNK Biomedical specializes in advanced B cell technology that allows for the selection and isolation of specific antibody-producing cells targeted toward challenging antigens. Their core product offerings leverage sophisticated platforms, namely ISAAC and VIVA|Screen, which facilitate a highly efficient mining process to identify rare antibody-secreting cells across various species, including humans, mice, rabbits, and dogs. The technology is designed to meet the needs of biopharmaceutical companies and research institutions that require unique therapeutic antibodies for the development of innovative treatments. BliNK Biomedical serves a global client base, focusing primarily on North America, Europe, and parts of Asia, where there is a significant demand for bespoke biologic therapies. The company's products are integral to research and development efforts aimed at addressing unmet medical needs in areas such as oncology, autoimmune diseases, and infectious diseases.BliNK Biomedical generated revenue of EUR 297,731.10 in 2023, with an EBITDA of EUR 377,824. The company primarily engages in business-to-business transactions with pharmaceutical companies and research organizations that utilize their antibody selection technology. Various partnerships may involve licensing agreements for their proprietary platforms, enabling access to advanced technology for antibody discovery. Each transaction typically encompasses an initial setup fee for technology integration, followed by recurring payments based on the identification of therapeutic candidates. Specific pricing structures are tailored to client needs and project scopes, reflecting the bespoke nature of the services offered.BliNK Biomedical plans to leverage its recent funding of EUR 1.65 mn from the SERIES A round led by Idinvest Partners to support the expansion of its product offerings and market reach. The company is focused on introducing new products aimed at enhancing its antibody selection technology, targeting a broader client base in North America and Europe by 2025. Additionally, the funding will facilitate further development of its proprietary platforms, ensuring robust support for pharmaceutical and research clients in their therapeutic development efforts.

## Funding rounds

- Series A, Feb 26, 2015, $17M — Kurma Partners, Cancer Research Technology Ltd., Valneva SE

## Investors

- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A
- Cancer Research Technology Ltd. — Series A
- Valneva SE — Series A